Thursday, October 20, 2022

Amgen Completes $3.7B Chemocentryx Buy

Thousand Oaks-based biotech giant Amgen said today that it has completed its $3.7 billion acquisition of ChemoCentryx, a biopharmaceuticals company which develops orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Amgen paid $52 per share in cash for Chemocentryx. Chemocentryx's lead product is TAVNEOS, an FDA-approved product which is used to treat severe active ANCA-associated vasculitis.